Newark, NJNCT07316192Now EnrollingIRB Ready

Hidradenitis Suppurativa (HS) Clinical Trial in Newark, NJ

Access cutting-edge hidradenitis suppurativa (hs) treatment through this clinical trial at a research site in Newark. Study-provided care at no cost to qualified participants.

Sponsored by Rutgers, The State University of New Jersey

Quick Self-Assessment

See if you qualify for this Newark location

Preparing your pre-screening questions…

Expert Care in Newark

Access hidradenitis suppurativa (hs) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related hidradenitis suppurativa (hs) treatment provided free

Apply for This Newark Location

Check if you qualify for this hidradenitis suppurativa (hs) clinical trial in Newark, NJ

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Newark

    Convenient for NJ residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Newark site if eligible
  4. 4Begin participation

About This Hidradenitis Suppurativa (HS) Study in Newark

Hidradenitis Suppurativa (HS) is a long-lasting skin condition that causes painful lumps and infections. In severe cases, patients need surgery to remove the affected skin. After surgery, a wound dressing called a wound matrix is placed over the area to help the skin heal. This study will compare two different wound matrices: Restrata®, which is the current standard treatment. Pelashield™ PainGuard™, a newer dressing that contains silver to reduce bacteria and lidocaine to help with pain. The goal of this research is to find out if Pelashield™ PainGuard™ helps patients heal better after surgery than Restrata®. We will look at: How quickly healthy granulation tissue (new healing tissue) forms How soon the wound is ready for the second surgery to apply a skin graft How often infections happen after surgery How much narcotic (opioid) pain medication patients need after surgery Patients who receive Pelashield™ PainGuard™ will be enrolled in the study going forward (prospective group). Patients who previously had surgery with Restrata® will be included through a review of their medical records (retrospective group). No additional procedures will be done outside of standard surgical care.

Sponsor: Rutgers, The State University of New Jersey

Who Can Participate

Inclusion Criteria

Adults (≥18 years) with a confirmed clinical diagnosis of HS requiring wide surgical excision.
Ability to provide informed consent in English.
Willingness and ability to attend routine postoperative follow-up visits to monitor healing and readiness for second-stage closure.

Exclusion Criteria

Non-English-speaking patients (due to consent and follow-up communication limitations).
Known allergy or hypersensitivity to wound matrix components (polyvinyl alcohol), local anesthetics, or silver.
Known sensitivity to lidocaine or history of cardiac conditions contraindicating lidocaine use (e.g., severe heart block, Adams-Stokes syndrome, Wolff-Parkinson-White syndrome).
Pregnancy or active breastfeeding.
Severe immunosuppression (e.g., chemotherapy within 3 months, solid organ transplant, uncontrolled HIV with CD4 \<200, or chronic systemic steroids \>10 mg prednisone-equivalent/day).
Uncontrolled diabetes (most recent HbA1c \>10% if available within 3 months).
Active systemic infection or sepsis at time of surgery.
Inability to complete postoperative follow-up through second-stage closure (e.g., plans to relocate).

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Newark?

Yes, this clinical trial (NCT07316192) has an active research site in Newark, NJ that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Hidradenitis Suppurativa (HS) Treatment Options in Newark, NJ

If you're searching for hidradenitis suppurativa (hs) treatment options in Newark, NJ, this clinical trial (NCT07316192) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Newark research site is actively enrolling participants for this clinical trial. You'll receive care from experienced hidradenitis suppurativa (hs) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all hidradenitis suppurativa (hs) clinical trials near you to find additional studies recruiting in your area.

More Alzheimers Disease Trials in Newark, NJ

See all alzheimers disease clinical trials recruiting in Newark — not just this study.

Browse Alzheimers Disease Trials in Newark →

Ready to Join in Newark?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Newark, NJ